89BIO, INC. (ETNB) News
Filter ETNB News Items
ETNB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ETNB News Highlights
- ETNB's 30 day story count now stands at 5.
- Over the past 13 days, the trend for ETNB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and PRE are the most mentioned tickers in articles about ETNB.
Latest ETNB News From Around the Web
Below are the latest news stories about 89BIO INC that investors may wish to consider to help them evaluate ETNB as an investment opportunity.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,000 shares of the Company’s common stock to two new employ |
89bio, Inc.'s (NASDAQ:ETNB) one-year returns climbed after last week's 7.0% gain, institutional investors must be happyKey Insights Significantly high institutional ownership implies 89bio's stock price is sensitive to their trading... |
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesSAN FRANCISCO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its previously announced upsized underwritten public offering of 17,567,567 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 2,432,432 share |
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded WarrantsSAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 15,135,135 shares of its common stock at a public offering price per share of $9.25 and, in lieu of common stock to a certain investor, pre-fund |
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsSAN FRANCISCO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stoc |
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024—Alignment reached on key elements of the NASH development strategy, including accelerated approval pathway for both F4 and F2-F3 NASH patients using histology— —Outcomes trial in F4 cirrhotic NASH patients expected to support full approval across F2-F4 NASH; potential to accelerate timeline to outcomes readout based on agreement with FDA on modified definition of some events— —Safety database will be inclusive of data from the ongoing SHTG Phase 3 program— —Trials to include patients on backgro |
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injury/inflammation and fibrosis in NASH patients with fibrosis stage F2-F3— —Subgroups of patients treated with pegozafermin on background GLP-1-based therapies and patients with compensated cirrhosis (F4) each showed robust benefits at week 48— —Pegozafermin continued to demonstrate a favorable safety and tolerability pro |
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx ConferenceSAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 6th Annual Evercore HEALTHCONx Conference on Tuesday, November 28, 2023 at 8:45 AM ET and participate in one-on-one investor meetings. The webcast of the firesid |
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4) patients at week 24— —A responder analysis suggests that responses in NITs were correlated with fibrosis improvement— —Pegozafermin continued to demonstrate a best-in-class tolerability profile— SAN FRANCISCO, Nov. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the de |
89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 2023Financial Results Indicate Higher Investment in Clinical Development |